September 9, 2026
CaaMTech Crystallographically Characterizes Tryptamines Found In “Magic Mushroom” Edibles
4-HO-DET and 4-AcO-DET are psychedelic synthetic tryptamines increasingly being identified in consumer products by third-party lab tests
September 9, 2026
4-HO-DET and 4-AcO-DET are psychedelic synthetic tryptamines increasingly being identified in consumer products by third-party lab tests
August 25, 2026
Pioneering research in monoalkyltryptamines builds foundation for next-generation serotonergic therapeutics
July 15, 2025
4-HO-DiPT is the principal active metabolite of 4-glutarato-DiPT, a prodrug currently undergoing Phase 2 clinical trials
July 9, 2025
New research from CaaMTech and collaborators reveals previously unknown terpenoids produced by specific enzymes in Psilocybe cubensis mushrooms
April 22, 2025
Industry veteran Charmaine Lykins to helm Transneural as it transforms the treatment of neuropsychiatric disorders
January 16, 2025
A new research paper by scientists from CaaMTech, NIDA, RTI, UMass Dartmouth and The Medical College of Wisconsin furthers tryptamine SAR understanding
November 14, 2024
CaaMTech’s new clinical trial design solves the emergent functional unblinding problems plaguing psychedelic medicine developers
March 27, 2024
Dr. Sackett also serves as the Director of the University of Washington Center for Novel Therapeutics in Addiction Psychiatry
September 21, 2023
Genomic sequences of various Psilocybe species revealed an unexpected wealth of genes encoding sesquiterpene synthases
September 14, 2023
The American Chemical Society will host the Chemistry of Psychedelics symposium at the 2023 Rocky Mountain Regional Meeting Sept. 14–17 the University of Wyoming